Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Novasep, a supplier of services and technologies for the life sciences industry, announced a €6.1 million investment at its Mourenx facility(Pyrénées-Atlantiques – France). This investment will modernize its API manufacturing facility.
read more
Takara Bio Inc. announced a License and Supply Agreement with BioNTech Cell & Gene Therapies GmbH ("BioNTech"), a BioNTech SE company (www.BioNTech.de), Germany, under which Takara Bio grants BioNTech a commercial license to use applicable patents ...
read more
Veradigm®, a healthcare data and technology company and business unit of Allscripts Healthcare Solutions, and PRA Health Sciences Inc., a global contract research organization, announced the creation of the industry’s leading electronic healthcare ...
read more
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it has reached an agreement to acquire ...
read more
Samsung Biologics, a contract development and manufacturing organization (CMDO), celebrated the one-year mark of Live Virtual Tour (LVT), a platform to provide remote site inspections for clients and regulatory agencies. The tool was developed and ...
read more
CellPoint, a cell therapy company developing CAR-T therapeutics for use at the point-of-care, announces an agreement with Lonza's Personalized Medicine Business Unit to employ Lonza's Cocoon® Platform for clinical manufacturing of CellPoint's CAR-T ...
read more
Breckenridge Pharmaceutical, Inc. announced the signing of a multi-product agreement with Aggrega Pharma, LLC. under which Aggrega will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.
read more
Genezen Laboratories, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has broken ground on a new multiphase master...
read more
Chemomab Therapeutics,Ltd., a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a global Biopharmaceutical Contract Development ...
read more
ViiV Healthcare and Halozyme Therapeutics, Inc. announced a global collaboration and license agreement that gives exclusive access to Halozyme’s ENHANZE® drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for specific ...
read more
Leidos, a Fortune 500® science and technology leader, was recently awarded a new prime contract by the Centers for Disease Control and Prevention (CDC) to provide bioinformatics and scientific computing support services. The firm-fixed-price contract...
read more
Danaher Corporation announced that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or ...
read more
Syneos Health® expanded its Decentralized Clinical Trial capabilities to include a dedicated Decentralized Clinical Trials Site Advocacy Group, continuing the momentum for Decentralized Solutions demonstrated by the recent acquisition of Illingworth ...
read more
ProBioGen and LAVA Therapeutics N.V. announced the closing of a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA's pipeline.
read more
ValenzaBio, a biopharmaceutical company developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, and Lonza announced that the companies have a manufacturing agreement in place.
read more